Christine Hallgreen

Københavns Universitet

Denmark

Research Interests

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (16)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (8)

Helle Christiansen

Københavns Universitet

DENMARK

View details

Carlos E. Durán

University Medical Center Groningen

NETHERLANDS

View details

Jonathan Kimmelman

McGill University

CANADA

View details

Shahab Abtahi

University of Maastricht

NETHERLANDS

View details

Peter Mol

Professor Drug Regulatory Science

University Medical Center Groningen

NETHERLANDS

View details

Helga Gardarsdottir

Associate professor

Utrecht University

NETHERLANDS

View details

Mathias Møllebæk

Københavns Universitet

DENMARK

View details

Morten Andersen

Københavns Universitet

DENMARK

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Christine Hallgreen

Research Interests

Contact this professor

Articles (16)

Implementation of electronic distribution of Direct Healthcare Professional Communications (DHPCs) by the Danish Medicines Agency

Understanding the Work of the Pharmacovigilance Risk Assessment Committee (PRAC)

Populations Addressed in Vaccines Approved via the European Medicines Agency

The life cycle of vaccines evaluated by the European Medicines Agency

Impact of the 2018 revised Pregnancy Prevention Programme by the European Medicines Agency on the use of oral retinoids in females of childbearing age in Denmark, Italy, Netherlands, and Spain: an interrupted time series analysis

Impact of 2018 EU Risk Minimisation Measures and Revised Pregnancy Prevention Programme on Utilisation and Prescribing Trends of Medicinal Products Containing Valproate: An Interrupted Time Series Study

Regional Disparity in First-in-Class Anticancer Drug Development in the US, EU, and Japan

Regional Disparity in First-in-Class Anticancer Drug Development in the US, EU, and Japan

Medication Adherence Measurement Methods in Registration Trials Supporting the Approval of New Medicines: A Cross‐Sectional Analysis of Centralized Procedures in the European Union 2010–2020

Impact of regulatory interventions to restrict the combined use of renin–angiotensin system blockers: A Danish nationwide drug utilisation study

New Information on Old Medicinal Products: A Cross-Sectional Analysis of Guidance for Paediatric Use for Substances on the European Priority List of Off-Patent Medicinal Products

Guidance for pediatric use in prescription information for novel medicinal products in the EU and the US

Hydroxyzine Initiation Following Drug Safety Advisories on Cardiac Arrhythmias in the UK and Canada

Influence of drug safety advisories on drug utilisation

Mandatory requirements for pediatric drug development in the EU and the US for novel drugs

Status of Planned and Ongoing Paediatric Trials Investigating COVID-19 Vaccines

Collaborators (8)

Helle Christiansen

Carlos E. Durán

Jonathan Kimmelman

Shahab Abtahi

Peter Mol

Helga Gardarsdottir

Mathias Møllebæk

Morten Andersen

Make your next move.